STUDY OF SERUM BIOCHEMICAL BONE MARKERS IN PATIENTS OF CARCINOMA BREAST UNDERGOING CHEMOTHERAPY AT CIMS, BILASPUR

Dr. Chandrahas Dhruw; Dr. Vijay Kumar Manwani

Volume : IX, Issue : VI, June - 2019

STUDY OF SERUM BIOCHEMICAL BONE MARKERS IN PATIENTS OF CARCINOMA BREAST UNDERGOING CHEMOTHERAPY AT CIMS, BILASPUR

Dr. Chandrahas Dhruw, Dr. Vijay Kumar Manwani

Abstract :

Background Breast cancer is the most common cancer and the leading cause of cancer–related deaths among women worldwide. The annual global incidence of east cancer is estimated to be >1.3 million cases and approximately 465,000 women die of this disease every year. Osteoporosis is a common chronic problem in postmenopausal women that increases the risk for spinal compression fractures and fractures of the femoral neck, causing life–threatening complications. Cancer–induced osteoporosis is a long–term complication associated with cancer therapy that can directly or indirectly affect bone metabolism. Objective To analyze and compare the Serum Biochemical Bone Markers in Patients of Carcinoma Breast before and after Chemotherapy. Material & Method: This prospective clinical study involves 27 histopathologically proven cases of carcinoma east patients which were conducted during October 2017 to August 2018 to estimate the Serum Biochemical Bone Markers in Patients of Carcinoma Breast before and after chemotherapy. The categorical clinical characteristics between the two treatments are compared using chi–square test. Result: in this study the Majority of the patients had stage IIIB and IIB disease 12 out of 27(44.4%) patients presented with IIIB disease, 9 out of 27(33.3%) belongs to stage IIB, 4 out of 27 (14.8) were in IIIA, 3 patients out of 27(11.1%) had IIIC disease. Majority of the patients, i.e. 88.8% patients (24/27) had Serum Calcium in normal range. None of the patients had hypocalcaemia (Serum Calcium <8.5mg/dl), 3 patients out of 27(11.1%) had hypercalcaemia, i.e. >11.o mg/dl. In patients completing CT and follow–up, 95.2% (20/21) had Serum Calcium in normal range with mean ofa10.10 ± .72.Only one patient had hypercalcaemia (Serum Calcium >11.0mg/dl). The mean pre–treatment Serum Phosphorus 3.59mg/dl in all 27 patients and 3.44±0.68mg/dl in patients completing treatment. The maximum and minimum values were 4.93 mg/dl and 0.8 mg/dl respectively. Approximately 30% patients (8/27), had serum Alkaline Phosphatase level in the range of 200–300 U/L. The mean serum Alkaline Phosphatase level was 341.41 ± 167.35 in all 27 patients; whereas in patients completing treatment it was 184±57.31 U/L. Conclusion In our study we found that most of the patients with newly diagnosed carcinoma east had pre–existing osteopenia and osteoporosis. In patients completing chemo radiotherapy, significant difference was seen between pre–treatment and post–treatment serum Calcium levels among patients in postmenopausal age group. Significant difference was also seen between pre–treatment and post–treatment Serum Phosphorus levels among patients in both premenopausal and postmenopausal groups. No statistically significant change was seen in Serum Alkaline Phosphatase levels with regard to premenopausal and postmenopausal patient groups, before and after treatment